Jasper Therapeutics Discounted Cash Flow

Jasper Therapeutics's discounted cash flow stands at $1.4. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Discounted cash flow values JSPR by forecasting cash the business could generate and bringing those cash flows to present value. Stockcircle's latest estimate is $1.4, implying the shares look undervalued by about 102.1%. Pair DCF with P/E, growth, and balance-sheet metrics before making a decision.

The history chart shows how Jasper Therapeutics's DCF fair value evolved across reporting periods, while the comparison chart places JSPR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.